Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients

BACKGROUND: A cure for the heterogeneous hematological malignancy multiple myeloma (MM) is yet to be developed. To date, the early risk factors associated with poor outcomes in MM have not been fully elucidated. Studies have shown an aberrant complement system in patients with MM, but the precise as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lihua, Ling, Xiaosui, Li, Fan, Yang, Tonghua, Shi, Keqian, Zhao, Shixiang, Yu, Liqun, Li, Zengzheng, He, Haiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891941/
https://www.ncbi.nlm.nih.gov/pubmed/35250324
http://dx.doi.org/10.1177/11795549221079171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891941/
https://www.ncbi.nlm.nih.gov/pubmed/35250324
http://dx.doi.org/10.1177/11795549221079171

Ejemplares similares